Investors

Overview

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Shareholder Tools

Latest News
03.25.24
OpGen Announces Acquisition of Preferred Stock by David Lazar
11.14.23
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
10.12.23
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

btn News

See All News

Upcoming Events
More events are coming soon.

btn Events

See all events